8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General151 citations

J Mol Histol 56(1):29, 2024

Bioeffects Seen

Authors not listed · 2024

Share:

This RSV vaccine study was incorrectly classified as EMF research and provides no electromagnetic field exposure data.

Plain English Summary

Summary written for general audiences

This study appears to be misclassified in the EMF Research Hub database. The research actually evaluated the effectiveness of nirsevimab, a monoclonal antibody treatment for respiratory syncytial virus (RSV) in infants, finding 90% effectiveness against RSV-related hospitalizations. This pharmaceutical intervention study has no connection to electromagnetic field exposure or EMF health effects.

Why This Matters

This study highlights a critical issue with research databases and classification systems. When legitimate medical research gets miscategorized as EMF-related, it creates confusion and dilutes the focus on actual electromagnetic field health studies. The reality is that proper study classification matters enormously for researchers, policymakers, and the public trying to understand EMF science. This RSV vaccine effectiveness study, while important for infant health, provides zero insights into electromagnetic field exposure effects. Such misclassification undermines the credibility of EMF research databases and makes it harder for people to find relevant information about wireless radiation, power line fields, or other electromagnetic exposures that actually matter for daily life decisions.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2024). J Mol Histol 56(1):29, 2024.
Show BibTeX
@article{j_mol_histol_56129_2024_ce2442,
  author = {Unknown},
  title = {J Mol Histol 56(1):29, 2024},
  year = {2024},
  doi = {10.15585/mmwr.mm7309a4},
  
}
DOI: 10.15585/mmwr.mm7309a4PubMed: 38457312

Quick Questions About This Study

This appears to be a database classification error. The study examines nirsevimab antibody effectiveness against respiratory syncytial virus in infants, with no electromagnetic field exposure component or EMF-related findings whatsoever.
No, nirsevimab is a monoclonal antibody injection given to prevent RSV infection in infants. The treatment mechanism involves immune system enhancement, not electromagnetic field exposure or wireless technology.
There is no scientific evidence connecting RSV vaccination with electromagnetic field sensitivity. This study focused solely on preventing respiratory infections and measured no EMF-related health outcomes or exposure parameters.
No electromagnetic frequencies were tested. This research evaluated a pharmaceutical intervention (nirsevimab antibody) for preventing RSV hospitalizations in infants during their first respiratory virus season from October 2023 to February 2024.
The 90% effectiveness refers to nirsevimab's ability to prevent RSV-related hospitalizations, not electromagnetic field protection. This pharmaceutical study outcome has no connection to EMF exposure reduction or wireless radiation shielding effectiveness.